NASDAQ:RADX Radiopharm Theranostics Q2 2026 Earnings Report $2.41 0.00 (0.00%) Closing price 08/28/2026 04:00 PM EasternExtended Trading$2.48 +0.07 (+2.95%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Radiopharm Theranostics EPS ResultsActual EPS-$1.58Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARadiopharm Theranostics Revenue ResultsActual Revenue$0.46 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARadiopharm Theranostics Announcement DetailsQuarterQ2 2026Date1/28/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Radiopharm Theranostics Earnings HeadlinesRadiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsAugust 26, 2026 | globenewswire.comRadiopharm Theranostics (NASDAQ:RADX) Stock Price Down 8.4% - Here's WhyAugust 21, 2026 | americanbankingnews.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race. | Chaikin Analytics (Ad)Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialAugust 20, 2026 | globenewswire.comRadiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain MetastasesAugust 17, 2026 | finance.yahoo.comRADX: RAD101 Topline & FY:26 Cash FlowsAugust 3, 2026 | finance.yahoo.comSee More Radiopharm Theranostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Radiopharm Theranostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Radiopharm Theranostics and other key companies, straight to your email. Email Address About Radiopharm TheranosticsRadiopharm Theranostics (NASDAQ:RADX), Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology. The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types. Radiopharm Theranostics collaborates with academic centers and contract development and manufacturing organizations to advance candidates from preclinical studies through clinical trials, with an emphasis on safety, efficacy and scalable production. Headquartered in Alpharetta, Georgia, Radiopharm Theranostics conducts operations in the United States and is positioning itself for expansion into select international markets. Its management team brings together professionals with deep expertise in radiopharmaceutical chemistry, nuclear medicine and oncology drug development, underscoring the company’s commitment to advancing next-generation diagnostic and therapeutic solutions.View Radiopharm Theranostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherIREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings3 Financial Stocks Positioned for the Fed’s Next Move After Jackson HoleNutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
